BeiGene Calls for Greater Integration of Mental Health in Cancer Care After New Survey Reveals Gaps/Barriers for Patients and Survivors - Seite 2
The survey findings will be discussed today at “Cancer and Mental Health: The Science and Art of Whole Patient Health,” a BeiGene-hosted event featuring renowned experts. Topics of conversation will include the practice of mental healthcare in a cancer setting; and the impact of inequality and health equity on access, research opportunities, and clinical guidelines. Finally, the group will address policy changes needed to systemically integrate mental health and wellness into quality cancer care that serves the whole patient. BeiGene intends to utilize the survey’s comprehensive findings to advance these conversations with the advocacy community, healthcare providers and policymakers as part of the Company’s new program, Talk About It: Cancer and Mental Health.
For more information about the research findings and BeiGene’s new program, please visit http://www.beigene.com/for-patients/cancer-mental-health/.
*This meeting was not an official program of the ASH annual meeting.
About Talk About It: Cancer and Mental Health
BeiGene believes mental health support can improve quality of life and health outcomes for individuals impacted by cancer. Aimed at
patients and caregivers, healthcare professionals and policymakers, BeiGene’s new and comprehensive program, Talk About It: Cancer and Mental Health, is designed to elevate the important
intersection of mental health and cancer care. Talk About It will feature innovative empowerment strategies, advance public policy conversations, and inspire dynamic health equity
initiatives to support people throughout their entire cancer journey. To learn more about Talk About It, visit http:///www.beigene.com/for-patients/cancer-mental-health/.
Lesen Sie auch
About BeiGene
BeiGene is a global biotechnology company that is developing and commercializing innovative and affordable oncology medicines to improve treatment outcomes and access for
far more patients worldwide. With a broad portfolio, we are expediting development of our diverse pipeline of novel therapeutics through our internal capabilities and collaborations. We are
committed to radically improving access to medicines for far more patients who need them. Our growing global team of more than 9,000 colleagues spans five continents, with administrative offices in
Beijing, China; Cambridge, U.S.; and Basel, Switzerland. To learn more about BeiGene, please visit www.beigene.com and follow us on Twitter at @BeiGeneGlobal.